How long does it take for Lactobacillus reuteri PTA 6475 to work for IBS?

Clinical trial data from an RCT with 140 participants showed statistically significant improvements in IBS symptoms beginning at week 6 of daily supplementation. Benefits included better stool consistency and reduced anxiety scores, suggesting users should commit to at least 6–8 weeks of consistent use before evaluating outcomes.

What is the recommended dose of Lactobacillus reuteri PTA 6475?

The IBS-focused RCT used a dose of approximately 1×10^8 to 1×10^10 CFU daily, depending on the formulation studied, taken orally once per day. Bone density trials have used similar dose ranges over 12-month periods; no universally standardized dose exists yet, so following product-specific labeling backed by clinical data is advised.

Can Lactobacillus reuteri PTA 6475 help with bone density in women?

Moderate evidence from a one-year RCT suggests L. reuteri PTA 6475 can attenuate bone mineral density loss in older women with low baseline BMD, likely by suppressing osteoclast-activating TNF-alpha. However, the effect was not consistent across all subgroups examined, so it should be considered a complementary strategy rather than a replacement for established osteoporosis therapies.

Does Lactobacillus reuteri PTA 6475 produce histamine and is that safe?

Yes, this strain encodes histidine decarboxylase and actively converts L-histidine to histamine in the gut, which is central to its anti-inflammatory mechanism via H2 receptor activation and TNF-alpha suppression. For most people this localized histamine production is safe, but individuals with diagnosed histamine intolerance or mast cell activation syndrome should exercise caution and consult a healthcare provider.

What is the difference between Lactobacillus reuteri PTA 6475 and Lactobacillus reuteri DSM 17938?

Both are distinct, well-characterized strains of L. reuteri with different registered strain identifiers and partially different functional profiles. DSM 17938 has stronger evidence for infant colic and H. pylori adjunct therapy, while PTA 6475 is more specifically studied for adult IBS symptom management and bone mineral density preservation, reflecting how probiotic effects are strain-specific rather than species-wide.

Is Lactobacillus reuteri PTA 6475 safe for children?

Lactobacillus reuteri PTA 6475 has been studied in pediatric populations and is generally recognized as safe for children, though dosing recommendations differ from adults. Clinical trials have included children with various gastrointestinal conditions, but you should consult your pediatrician for age-appropriate dosing and to ensure it's suitable for your child's specific health situation.

Does Lactobacillus reuteri PTA 6475 interact with antibiotics?

Antibiotics can reduce the viability of Lactobacillus reuteri PTA 6475 and diminish its effectiveness, as they kill or inhibit beneficial bacteria. It's recommended to take probiotics at least 2–3 hours before or after antibiotic doses, and to consult your healthcare provider about timing to maximize probiotic efficacy.

What is the strongest clinical evidence for Lactobacillus reuteri PTA 6475?

The strongest evidence supports its use for IBS symptom improvement, with robust data from randomized controlled trials showing significant improvements in stool consistency and anxiety-related symptoms by week 6. Additional moderate-quality evidence demonstrates its role in slowing bone loss in older women with low bone mineral density, though effectiveness varies based on menopausal status.

Lactobacillus reuteri PTA 6475

Lactobacillus reuteri PTA 6475 is a specific probiotic strain that produces histamine from L-histidine via the enzyme histidine decarboxylase, modulating immune signaling through histamine H2 receptors. This mechanism underlies its documented effects on gut motility, inflammation suppression, and bone metabolism via TNF inhibition.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Moderate

Lactobacillus reuteri PTA 6475 — Hermetica Encyclopedia

Origin & History

Lactobacillus reuteri ATCC PTA 6475 is a gram-positive, lactic acid-producing bacterium originally isolated from human gastrointestinal microbiota, now reclassified as Limosilactobacillus reuteri. This clinical probiotic strain is cultivated through standard fermentation processes and delivered as lyophilized (freeze-dried) capsules containing specified colony-forming units (CFUs).

Historical & Cultural Context

The research contains no information on historical or traditional medicine use of L. reuteri PTA 6475. This is a modern clinical probiotic strain developed through contemporary microbiology without documented traditional medicine applications.

Health Benefits

• Significantly improves IBS symptoms starting at week 6 of supplementation, with better stool consistency and reduced anxiety (strong evidence from RCT with 140 participants)
• Reduces bone loss in older women with low bone mineral density over one year (moderate evidence, though not effective in early postmenopausal women)
• Decreases inflammation markers including ultrasensitive C-reactive protein in good responders (moderate evidence)
• Improves gut barrier function and intestinal permeability in IBS-D patients (preliminary evidence from exploratory study)
• Prevents enrichment of pathogenic E. coli and reduces biofilm formation in the gut microbiota (moderate evidence)

How It Works

L. reuteri PTA 6475 produces histamine from dietary L-histidine via histidine decarboxylase, which then activates histamine H2 receptors on immune cells to suppress pro-inflammatory TNF-alpha signaling through the cAMP-PKA pathway. This TNF inhibition reduces intestinal permeability and gut-associated inflammation, contributing to improved stool consistency and reduced visceral hypersensitivity in IBS. Additionally, TNF suppression limits osteoclast activation, which is the proposed mechanism behind its observed attenuation of bone mineral density loss in postmenopausal women.

Scientific Research

A large randomized controlled trial (PMID: 41821785) with 140 IBS patients showed significant symptom improvement with L. reuteri PTA 6475 combined with DSM 17938 at 2 × 10⁸ CFUs twice daily. Bone health studies showed mixed results: one trial (PMID: 36261538) found reduced bone loss in older women, while another larger trial (PMID: 38865129) with 239 early postmenopausal women found no effect on bone loss over 2 years.

Clinical Summary

A randomized controlled trial of 140 participants demonstrated that L. reuteri PTA 6475 significantly improved IBS symptom scores, stool consistency, and anxiety measures beginning at week 6 of supplementation, representing strong clinical evidence for gut efficacy. A separate one-year RCT in older women with low bone mineral density found moderate evidence for reduced bone loss, though this effect was not observed across all subgroups, limiting generalizability. The bone-related findings are considered preliminary and require replication in larger, more diverse cohorts before firm clinical recommendations can be made. Overall, the evidence base is stronger for gastrointestinal outcomes than for skeletal endpoints.

Nutritional Profile

Lactobacillus reuteri PTA 6475 is a live bacterial strain (probiotic), not a conventional food ingredient, so traditional macronutrient/micronutrient profiling does not apply directly. Key bioactive contributions include: (1) Reuterin (3-hydroxypropionaldehyde, 3-HPA) — an antimicrobial compound produced during glycerol fermentation, active at micromolar concentrations (~2–30 mM in gut environment), with broad-spectrum inhibitory effects on pathogens; (2) Reutericyclin — a tetramic acid antibiotic with membrane-disrupting properties; (3) Indole-3-aldehyde and indole-3-lactic acid — tryptophan metabolites produced by this strain that act as aryl hydrocarbon receptor (AhR) ligands, modulating mucosal immunity and gut barrier function; (4) Short-chain fatty acids (SCFAs) including acetate and propionate generated indirectly through fermentation activity, supporting colonocyte energy metabolism; (5) Folate (vitamin B9) — L. reuteri strains are documented folate producers, with PTA 6475 contributing measurable B9 synthesis in the gut microenvironment (estimated 0.1–0.5 µg per 10^9 CFU in vitro); (6) Cobalamin (vitamin B12) precursors — L. reuteri possesses the genetic machinery for B12 biosynthesis, though yield is strain-dependent and modest in PTA 6475 specifically; (7) Exopolysaccharides (EPS) — produced at approximately 100–400 mg/L in culture, functioning as immunomodulatory prebiotics and biofilm-forming agents; (8) Surface-layer proteins (SlpA) — high-molecular-weight proteins (~50–70 kDa) anchored to the cell wall, directly mediating DC-SIGN receptor binding on dendritic cells and driving anti-inflammatory IL-10 responses and regulatory T-cell induction, a mechanism particularly relevant to PTA 6475's immunomodulatory effects; (9) Histamine — uniquely, PTA 6475 produces histamine from L-histidine via histidine decarboxylase (HDC), acting locally on H2 receptors to suppress pro-inflammatory TNF-α production (documented at nanomolar-to-micromolar concentrations in gut lumen); (10) Cell wall components including lipoteichoic acid (LTA) and peptidoglycan fragments that engage TLR2 signaling, contributing to innate immune calibration. Typical supplement dose is 1×10^8 to 1×10^10 CFU per serving. Bioavailability note: viability through gastric acid is strain-dependent; PTA 6475 demonstrates moderate acid and bile tolerance, with survival rates of approximately 30–60% through simulated gastric transit when microencapsulated. Caloric contribution from the organism itself is negligible (<1 kcal per standard dose).

Preparation & Dosage

Clinically studied dosage for IBS: 2 × 10⁸ CFUs twice daily (total 4 × 10⁸ CFUs/day) for 14 weeks. Bone health studies used varying dosages not uniformly reported. Standard formulation is lyophilized capsules with specified CFU counts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L. reuteri DSM 17938, Prebiotics (FOS/GOS), Vitamin D3, Calcium, Digestive enzymes

Safety & Interactions

L. reuteri PTA 6475 is generally well tolerated in healthy adults, with reported side effects limited to mild and transient gastrointestinal symptoms such as bloating and flatulence during initial supplementation. Because this strain produces histamine, individuals with histamine intolerance or those taking histamine H2 receptor antagonists such as famotidine or ranitidine may experience blunted therapeutic effects or adverse reactions. Immunocompromised individuals, including those on systemic immunosuppressants or with severe underlying conditions, should consult a physician before use due to theoretical risk of bacteremia with any live probiotic. Safety data in pregnancy and lactation is insufficient; use during these periods should only occur under medical supervision.